235101-36-7

Basic information

• Product Name: 2-Amino-4-trifluoromethoxybenzothiazole
• Synonyms: 2-Amino-4-trifluoromethoxybenzothiazole;4-TrifluoroMethoxy-benzothiazol-2-ylaMine;Riluzole 4-Trifluoromethoxyl Impurity;4-(Trifluoromethoxy)benzo[d]thiazol-2-amine
• CAS NO: 235101-36-7
• Molecular Formula: C₈H₅F₃N₂OS
• Molecular Weight: 234.2
• Mol File: 235101-36-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 72 ºC
• Boiling Point: 296.277 °C at 760 mmHg
• Flash Point: 132.984 °C
• Appearance: /
• Density: 1.572
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 2-Amino-4-trifluoromethoxybenzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-trifluoromethoxybenzothiazole(235101-36-7)
• EPA Substance Registry System: 2-Amino-4-trifluoromethoxybenzothiazole(235101-36-7)

Safety Data

• Hazardous Substances Data: 235101-36-7(Hazardous Substances Data)

Usage

Uses

Riluzole 4-Trifluoromethoxy Isomer is an impurity of Riluzole (R510000), a neuroprotective agent. Modulates glutamatergic transmission. A glutamate release inhibitor. An anticonvulsant.

Upstream product

• 1535-75-7 2-trifluoromethoxy aniline 
• 1147550-11-5 ammonium thiocyanate 
• 175205-24-0 N-<2-(trifluoromethoxy)phenyl>thiourea 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors

A series of novel 4-phenoxyquinoline derivatives containing the benzo[d]thiazole-2-yl urea moiety were synthesized and evaluated for their cytotoxicity against the HT-29, MKN-45, and H460 cell lines. The structures of the target compounds were confirmed by 1H NMR and MS spectra. Most of them showed moderate to excellent potency against the three tested cell lines. Especially, compound 23 was identified a promising agent (c-Met IC50 = 17.6 nM), showing the most potent anticancer activities with IC50 values of 0.18, 0.06, and 0.01 μM against the HT-29, MKN-45, and H460 cell lines, respectively. The docking results of 23 with the c-Met kinase model 3LQ8 showed a specific binding mode between the ligand and the target protein.

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.